论文部分内容阅读
目的研究头孢吡肟联合万古霉素治疗社区获得性重症肺炎(SCAP)的疗效。方法将80例SCAP肺炎患者均分成两组,两组均给予头孢吡肟等基础治疗,治疗组在增加万古霉素治疗,两组疗程为7～14d。两组其他方面没有统计学差异(P>0.05),具有可比性。结果治疗组临床有效率85.2%,对照组仅为68.5%,两组比较差异具有统计学意义(P<0.05);治疗组体温、咳嗽咳痰、血常规和肺部啰音等症状改善明显优于对照组(P<0.05)。结论头孢吡肟与万古霉素具有协同抗菌作用,治疗社区获得性重症肺炎疗效显著,值得临床推广。
Objective To study the efficacy of cefepime combined with vancomycin in the treatment of community-acquired severe pneumonia (SCAP). Methods Eighty patients with SCAP pneumonia were divided into two groups, two groups were given cefepime and other basic treatment, the treatment group was treated with vancomycin, the two courses of treatment for 7 ~ 14d. There was no significant difference between the other two groups (P> 0.05), comparable. Results The clinical effective rate was 85.2% in the treatment group and 68.5% in the control group, with significant difference between the two groups (P <0.05). The symptoms such as body temperature, cough and sputum, blood routine and pulmonary rales in the treatment group improved obviously In the control group (P <0.05). Conclusion Cefepime has a synergistic antibacterial effect with vancomycin and has a significant therapeutic effect on community-acquired severe pneumonia. It is worthy of clinical promotion.